Work

EP11.02-07 Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial

Year: 2023

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.1169

Authors: D.H.E. Lee, J.S. Ahn, S.-H. Lin, A.L. Ortega Granados, C.S. Fuentes, C.-F. Chian, Z. Szijgyarto, N. Stjepanovic, L. Cho, S.M. Lim

Institutions: Samsung Medical Center, Sungkyunkwan University, Changhua Christian Hospital, Complejo Hospitalario de Jaén, Tri-Service General Hospital, National Defense Medical Center, GlaxoSmithKline (United States), Yonsei University, Severance Hospital, Yonsei University Health System, Yonsei Cancer Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045675

Cites:

Cited by:

Related to: 10